# Frances A. Shepherd
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/frances-a-shepherd/
## Facts
| Field | Value |
| --- | --- |
| Citations | 82,397 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 129 |
| i10-index | 530 |
| Last Known Institution | University Health Network |
| OpenAlex ID | https://openalex.org/A5075347427 |
| ORCID iD | 0000-0002-3610-3533 |
| Works | 1,116 |
## Researcher papers
Showing 12 of 25.
- [Erlotinib in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/erlotinib-in-previously-treated-non-small-cell-lung-cancer/)
- [Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group](https://scholariq.org/papers/lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-lace-collaborative/)
- [Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy](https://scholariq.org/papers/randomized-phase-iii-trial-of-pemetrexed-versus-docetaxel-in-patients-with-non/)
- [Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy](https://scholariq.org/papers/prospective-randomized-trial-of-docetaxel-versus-best-supportive-care-in/)
- [Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome](https://scholariq.org/papers/erlotinib-in-lung-cancer-molecular-and-clinical-predictors-of-outcome/)
- [Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer](https://scholariq.org/papers/vinorelbine-plus-cisplatin-vs-observation-in-resected-non-small-cell-lung-cancer/)
- [Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial](https://scholariq.org/papers/radiotherapy-plus-chemotherapy-with-or-without-surgical-resection-for-stage-iii/)
- [Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study](https://scholariq.org/papers/gene-expression-based-survival-prediction-in-lung-adenocarcinoma-a-multi-site/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes](https://scholariq.org/papers/large-scale-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
## Researcher university
- [University Health Network](https://scholariq.org/institutions/university-health-network/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.